Tandem Labs To Acquire PharmaKD, A Division Of Linden Technologies Specializing In Drug Metabolite And Biomarker Profiling

SALT LAKE CITY, Sept. 13 /PRNewswire/ -- Tandem Labs (http://www.tandemlabs.com), a leading contract research organization (CRO) providing bioanalytical and immunoanalytical testing for the pharmaceutical industry, and PharmaKD (http://www.pharmakd.com/), a Boston, Massachusetts-based division of Linden Technologies providing mass spectrometry-based pharmacokinetics and pharmacodynamics (PK/PD) for drug metabolite and biomarker profiling, announced today, September 13, 2006, that Tandem Labs has acquired PharmaKD. Under the agreement, Tandem Labs will retain key personnel, intellectual property portfolios, proprietary informatics, scientific instruments, and 7,000-square-feet of operational space from PharmaKD.